Taysha Gene Therapies, Inc. (TSHA) insider trading

By person

10 insiders · 66 transactions

53.4×

Sean Nolan holds 53.4 times base salary in stock. $34.54M of shares against $645.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean Nolan last reported holding, valued at $6.24, the price Common Stock was last bought or sold at on the open market here, on 10 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Paul B Manning

10% owner

$25.15M (13)

—

+$25.15M

6,195,139

1.90%

$38.66M

—

Sukumar Nagendran

President and Head of R&D

$83.50K (2)

$6.13M (9) scheduled

−$6.05M

936,410

0.2874%

$5.84M

—

Suyash Prasad

CMO and Head of R&D

—

$2.02M (12)

−$2.02M

530,589

0.1628%

$3.31M

—

Kamran Alam

Chief Financial Officer

—

$1.40M (14)

−$1.40M

1,442,131

0.4426%

$9.00M

—

John A Stalfort III

Director

$700.00K (2)

—

+$700.00K

2,060,849

0.6325%

$12.86M

+86.4%

Sean P. Nolan

Chief Executive Officer

$426.15K (2)

$840.20K (2)

−$414.05K

5,534,903

1.70%

$34.54M

+407.3%

R.A. Session II

10% owner

$529.10K (2)

$388.73K (6)

+$140.37K

8,871,747

2.72%

$55.36M

−2.8%

Phillip B. Donenberg

Director

$123.34K (2)

—

+$123.34K

241,289

0.0741%

$1.51M

—

Alison S Long

Director

—

127,178

0.0390%

$793.59K

—

Laura Sepp-Lorenzino

Director

—

127,178

0.0390%

$793.59K

—

Taysha Gene Therapies, Inc.

What the insiders did Net buying

By person